Benefits
Memory enhancement in healthy adults (BT-11 RCT)
A randomized double-blind placebo-controlled parallel-group study in healthy adults given BT-11 (Polygala tenuifolia root extract) capsules or placebo 3 times a day for 4 weeks. Between the two groups, only immediate recall on the K-CVLT was significantly better with BT-11. Within each group, most K-CVLT subtests improved significantly on placebo as well, so the placebo response was large. Recognition scores and errors on the SOPT improved with BT-11 and not with placebo, but those are within-group comparisons, not head-to-head ones. The published abstract does not report how many people took part. This is one specific Korean extract, so the result does not automatically transfer to any polygala product.
Cognitive enhancement in elderly (BT-11 RCT)
A randomized double-blind placebo-controlled comparison in elderly adults given BT-11 vs placebo found total CERAD scores significantly more increased in the BT-11 group than placebo. The trial was small, BT-11 n=28 versus placebo n=25, and it comes from the same Seoul group and senior author as the healthy-adult study, so it is a companion study rather than an independent replication. It again tests one specific extract, not polygala in general.
Cognitive and daily-function scores (two-herb combination)
A 2024 meta-analysis pooled 16 Chinese trials in 1,103 people diagnosed with Alzheimer's disease, and it tested a two-herb pair, Polygala tenuifolia with Acorus tatarinowii, not polygala on its own. Added on top of the participants' prescription medicines, the herb pair was linked to better MMSE, ADL and ADAS-cog scores. Used on its own, the herb pair was no better than those medicines. The authors state that the very low to low quality of the evidence limits confidence, and the MMSE pooling was highly inconsistent (I-squared 86%). This is combination research in people already on drug therapy; it is not a reason to expect polygala to treat or prevent any disease.
Calming use in tradition and animal work
Traditional Chinese practice has long used polygala in calming formulas, and a review of Polygalae Radix lists hypnotic-sedative and antidepressant-like activity among the effects reported for its compounds and extracts in laboratory work. That is traditional and preclinical only. No human trial cited on this page measured mood, anxiety or sleep, so calming effects in people are unproven.
Neuroprotection (preclinical evidence)
Tenuigenin, tenuifolin, polygalasaponins, and onjisaponin B demonstrate β-amyloid reduction, antioxidant effects, neurotransmitter regulation, synaptic function improvement, anti-inflammatory effects, neuronal apoptosis inhibition, and autophagy modulation in cell and animal studies. None of it is human evidence, and it does not show that polygala treats or prevents dementia, Alzheimer's, Parkinson's or any other disease. The laboratory work is simply broader than the small human record behind this herb.
Mechanism of action
Acetylcholinesterase inhibition (cholinergic enhancement)
Polygala tenuifolia extract demonstrates acetylcholinesterase inhibitory activity in test-tube work, which would increase synaptic acetylcholine availability. That is a laboratory finding only, and it does not make polygala act like a prescription medicine. Supports cognitive enhancement claims via cholinergic pathway involved in encoding new information.
BDNF and MAP kinase pathway activation
Polygalasaponin XXXII (PGS32) and other actives activate ERK/CREB pathway leading to elevated brain-derived neurotrophic factor (BDNF), which matters for synaptic plasticity and learning. Long-term potentiation was also increased in dentate gyrus recordings. All of this is cell and rodent work; none of the human trials on this page measured BDNF or plasticity.
GABA-modulating activity (sedative effects)
Polygalasaponins extract shows GABAergic modulation, with sedative and calming behavior in animal models. That is the proposed basis for the traditional calming use, and no human trial cited here tested sleep or anxiety. Some people report mild sedation, which fits the traditional calming use.
Nerve growth factor (NGF) release enhancement
P. tenuifolia extract enhances NGF release from astroglial cells in culture, which supports neuronal survival, growth and synaptic maintenance. Combined with the BDNF findings, that is the neurotrophic rationale people cite for polygala. It is laboratory work, and it says nothing about preventing dementia or any other disease in people.
Clinical trials
Randomized double-blind placebo-controlled parallel-group study (Lee JY, Kim KY, Shin KY, Won BY, Jung HY, Suh YH 2009, Neurosci Lett 454(2):111-114, doi:10.1016/j.neulet.2009.03.024, PMID 19429065).
Healthy Korean adults received BT-11 (Polygala tenuifolia Willdenow root extract) capsules or placebo 3 times daily for 4 weeks; the published abstract does not report how many people took part. Korean version of California Verbal Learning Test (K-CVLT) for verbal memory and Self-Ordered Pointing Test (SOPT) for working memory.
Between groups, only immediate recall on the K-CVLT was significantly better with BT-11. Within groups, most K-CVLT subtests rose significantly on placebo as well, so the placebo response was large. Recognition scores and SOPT errors improved with BT-11 and not with placebo, but those are within-group comparisons. The same authors had previously reported this extract in rat amnesia models, which is animal work, not a human result.
Randomized double-blind placebo-controlled comparison (Shin KY, Lee JY, Won BY, Jung HY, Chang KA, Koppula S, Suh YH 2009, Neurosci Lett 465(2):157-159, doi:10.1016/j.neulet.2009.08.033, PMID 19699261).
Elderly humans randomized to BT-11 (n=28) or placebo (n=25). Used CERAD (Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet) and MMSE assessments.
Total CERAD scores significantly more increased in BT-11-treated group than in placebo group. Word list recognition, constructional praxis and recall, and the modified Boston naming test also improved more than in the placebo group. This is a small trial, 53 people in total, from the same Seoul group and senior author as the healthy-adult study, so it is a companion study and not an independent replication. The abstract does not report the dose or how long treatment lasted.
Evidence review and pooled analysis (Zhang Y, Tian J, Ni J, Wei M, Li T, Shi J 2024, Front Pharmacol 14:1268000, doi:10.3389/fphar.2023.1268000, PMID 38283842). PROSPERO registration CRD42023444156.
Evidence review of Chinese clinical trials of Polygala tenuifolia + Acorus tatarinowii combination treatment for Alzheimer's disease. Sixteen trials, 1,103 participants, eight databases searched. Outcomes: MMSE, ADL, ADAS-cog. Cochrane risk of bias assessment.
Added on top of conventional drugs, the herb pair was linked to better MMSE (mean difference 2.57), ADL and ADAS-cog scores. Used alone, the herb pair was comparable to the conventional drugs, meaning no better than them. The authors state that the very low to low quality of the available evidence limits confidence in the findings, and the MMSE pooling was highly inconsistent (I-squared 86%). Adverse events were not increased. The result belongs to a two-herb combination, not to polygala on its own.